reports
Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin ...
Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin for Treatment of MASH Cirrhosis and Portal Hypertension NORCROSS, Ga., June 10, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:GALT), the leading developer of therapeutics that target galectin-3 for patients with MASH cirrhosis and portal hypertension, today announced that it will host a virtual key opinion leader (KOL) event on Monday, June 16, 2025 at 12:00 PM ET. To register, The event will focus on the unmet need and current treatment landscape for metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal hy...
Galectin Therapeutics Reports Financial Results for the Quarter Ended ...
Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2025 and Provides Business Update NORCROSS, Ga., May 15, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended March 31, 2025. Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics, stated “This quarter, we remained laser-focused on advancing additional analyses for belapectin. I was extremely encouraged by the feedback we received last week a...
Galectin Therapeutics Presented NAVIGATE Trial Results at the European...
Galectin Therapeutics Presented NAVIGATE Trial Results at the European Association for the Study of the Liver (EASL) 2025 Congress Data presentation included efficacy and biomarker analyses from the NAVIGATE trial (n=287). Belapectin 2 mg/kg demonstrated a statistically significant reduction in new varices at 18 months in the per-protocol population (p=0.04). Significantly fewer patients in the belapectin treatment arms experienced worsening of liver stiffness as measured by FibroScan®, reinforcing the potential beneficial effect of belapectin in halting the progression of MASH cirrhosis....
Galectin Therapeutics to Present at the European Association for the S...
Galectin Therapeutics to Present at the European Association for the Study of the Liver (EASL) 2025 Congress NORCROSS, Ga., April 15, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:GALT), the leading developer of therapeutics that target galectin-3 for patients with MASH cirrhosis and portal hypertension, today announced that it will attend the EASL 2025 meeting and deliver a scientific presentation in the late-breaking oral presentation session. The meeting will be held May 7-10, 2025, in Amsterdam, Netherlands. “We are excited that data from our NAVIGATE study, evaluating belapectin, a galectin-3...
Galectin Therapeutics Reports 2024 Financial Results and Provides Busi...
Galectin Therapeutics Reports 2024 Financial Results and Provides Business Update NORCROSS, Ga., March 31, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the year ended December 31, 2024. Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics, said “In the U.S. approximately 5 million adults are affected by MASH cirrhosis and clinically significant portal hypertension. The need for new treatments that can...
Galectin Therapeutics Reports Significant Reduction in New Varices wit...
Galectin Therapeutics Reports Significant Reduction in New Varices with Belapectin in U.S. Patient Population from the NAVIGATE Trial Additional analysis of data from the NAVIGATE trial showed statistically significant 68.1% (p=0.02) reduction in the incidence of new varices with belapectin vs placebo in per-protocol patients (completers) enrolled in the U.S.New estimates indicate around 3 million adults in the U.S. suffer from MASH cirrhosis and clinically significant portal hypertension1, for which there are no FDA approved therapiesFull analysis of the NAVIGATE trial is ongoing; addition...
Galectin Therapeutics to Present at the 2025 MASH-TAG Conference
Galectin Therapeutics to Present at the 2025 MASH-TAG Conference NORCROSS, Ga., Jan. 10, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that the top-line results of the NAVIGATE trial in patients with MASH cirrhosis and portal hypertension will be presented during the 2025 MASH-TAG Conference, being held January 9-11, 2025 in Park City, Utah. Additionally, Company’s executive leadership will be hosting one-on-one meetings in San Franscico January 13-16, 2025, during JP Morgan Healthcare Conference and is looki...
Galectin Therapeutics Announces Top-Line Results of NAVIGATE Clinical ...
Galectin Therapeutics Announces Top-Line Results of NAVIGATE Clinical Trial Evaluating Belapectin in Patients with Cirrhotic Portal Hypertension Caused by MASH In the pre-specified per-protocol population, belapectin showed a statistically significant reduction (p-value < 0.05) in development of esophageal varices in 2mg/kg cohort compared to placeboWhile there was a favorable trend for incidence of varices in the primary end point intent-to-treat population, belapectin did not achieve statistical significanceBelapectin was overall well tolerated with no safety signals; incidence of adverse...
Galectin Therapeutics Presents Three Abstracts at the American Associa...
Galectin Therapeutics Presents Three Abstracts at the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting Patient population for the NAVIGATE trial is based on non-invasive tests and clinical criteria utilizing latest treatment guidelines for portal hypertension in MASH cirrhosisBlinded central review system can be effectively set-up for evaluation of esophagogastoduodenoscopy (EGD) in large multi-center trial of patients with MASH cirrhosis and portal hypertension, facilitating utilization of this outcome as a critical endpoint in portal hypertension trialsAppro...
Galectin Therapeutics Reports Financial Results for the Quarter Ended ...
Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2024 and Provides Business Update NAVIGATE trial on track for top-line results in December 2024 NORCROSS, Ga., Nov. 14, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the quarter ended September 30, 2024. Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics, said “This past quarter, we remained laser-focus on advancing the NAVIGATE trial of belapectin in...
Galectin Therapeutics Announces Acceptance of Three Abstracts for the ...
Galectin Therapeutics Announces Acceptance of Three Abstracts for the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting NORCROSS, Ga., Oct. 15, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that three abstracts from ongoing Phase 2b/3 adaptive, NAVIGATE trial in patients with MASH cirrhosis and portal hypertension have been accepted for poster presentation at the American Association for the Study of Liver Diseases (AASLD)’s annual meeting, 2024 Liver Meeting, being held November...
Galectin Therapeutics to Participate in the H.C. Wainwright MASH Confe...
Galectin Therapeutics to Participate in the H.C. Wainwright MASH Conference NORCROSS, Ga., Sept. 30, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that Joel Lewis, Chief Executive Officer and Khurram Jamil, M.D., Chief Medical Officer, will be attending the H.C. Wainwright MASH Investor Conference being held October 7, 2024. Dr. Jamil will be sharing the latest updates on clinical programs and pipeline advancement on October 7, 2024 at 10:00 AM ET. The webcast of the presentation can be accessed or through ...
Galectin Therapeutics to Present at the H.C. Wainwright 26th Annual Gl...
Galectin Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference NORCROSS, Ga., Sept. 03, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that Joel Lewis, Chief Executive Officer and Khurram Jamil, M.D., Chief Medical Officer, will be attending the H.C. Wainwright 26th Annual Global Investment Conference being held September 9-11, 2024 in New York, NY. Dr. Jamil will be providing a company presentation on September 9, 2024 at 12:00 PM ET. The webcast of the presentation can be...
Galectin Therapeutics Reports Financial Results for the Quarter Ended ...
Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2024 and Provides Business Update NAVIGATE trial on track for interim top-line analysis in December 2024 NORCROSS, Ga., Aug. 13, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the quarter ended June 30, 2024. Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics, said, “We continued to advance the NAVIGATE Phase 2b/3 trial of belapectin in the first half of 2...
Galectin Therapeutics Appoints Khurram Jamil, M.D. to Chief Medical Of...
Galectin Therapeutics Appoints Khurram Jamil, M.D. to Chief Medical Officer NORCROSS, Ga., Aug. 01, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced the appointment of Khurram Jamil, M.D., an accomplished senior executive with expertise in liver disease to Chief Medical Officer effective immediately. Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics, said “We are very excited to elevate Dr. Jamil to Chief Medical Officer. After joining us in March 2024 as Vice President Clinical Devel...
Galectin Therapeutics to Present at the European Association for the S...
Galectin Therapeutics to Present at the European Association for the Study of the Liver (EASL) 2024 Congress NORCROSS, Ga., June 04, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:GALT), the leading developer of therapeutics that target galectin-3, today announced that it will attend the EASL 2024 meeting and deliver a scientific presentation. The meeting will be held June 5-8, 2024, in Milan, Italy. “At this year’s meeting we are again pleased to share important scientific information with the hepatology community. Through the knowledge captured from our belapectin program, we are adding knowledge o...
- Jonathan Moreland
CPSI COMPUTER PROGRAMS & SYSTEMS INC.
CNMD CONMED CORPORATION
BCRX BIOCRYST PHARMACEUTICALS INC.
AVD AMERICAN VANGUARD
AQMS AQUA METALS INC
NEWT NEWTEK BUSINESS SERVICES INC.
SABR SABRE CORP.
AAOI APPLIED OPTOELECTRONICS INC.
RIGN TRANSOCEAN LTD.
NQP NUVEEN PENNSYLVANIA INVESTMENT QUALITY MUNICIPAL FUND INC.
ZOM ZOMEDICA PHARMACEUTICALS CORP
ARKR ARK RESTAURANTS CORP.
HAIN THE HAIN CELESTIAL GROUP
UBFO INC.
AFB UNITED SECURITY BANCSHARE
MAV ALLIANCEBERNSTEIN NATIONAL MUNICIPAL INCOME FUND
NEPH PIONEER MUNICIPAL HIGH INCOME ADVANTAGE TRUST
MHI NEPHROS INC
EYE PIONEER MUNICIPAL HIGH INCOME TRUST
CDLX NATIONAL VISION HOLDINGS
NWPP CARDLYTICS INC
EAF NEW PEOPLES BANKSHARES INC.
ISDR GRAFTECH INTERNATIONAL
AVRO ISSUER DIRECT CORP.
FSK AVROBIO
RRBI FS KKR CAPITAL CORP
GO RED RIVER BANCSHARES
FNWB GROCERY OUTLET HOLDING
HQL FIRST NORTHWEST BANCORP
HQI TEKLA LIFE SCIENCES INVESTORS
TLS HIREQUEST INC.
FTHM TELOS
GRNT FATHOM HOLDINGS
RPHM GRANIT SKOPKE
TMCI RENEO PHARMACEUTICALS
WES INC.
HUMA TREACE MED CONCEPTS INC
BGS WESTERN MIDSTREAM PARTNERS LP
DCGO HUMACYTE INC
TRDA B&G FOODS
BHVN INC.
VPV DOCGO INC
VSTS_w ENTRADA THERAPEUTICS INC
BHRB BIOHAVEN LTD
IZEA INVESCO PA VALUE MUNI INC TST
MIO VESTIS CORPORATION
BURKE HERBERT FINANCIAL SERVICES CORP
IZEA WORLDWIDE INC
PIONEER MUN HIGH INCOME OPPORTUNITIES FD INC
- Jonathan Moreland
RIGN TRANSOCEAN LTD.
NQP NUVEEN PENNSYLVANIA INVESTMENT QUALITY MUNICIPAL FUND INC.
AFB ALLIANCEBERNSTEIN NATIONAL MUNICIPAL INCOME FUND
MAV PIONEER MUNICIPAL HIGH INCOME ADVANTAGE TRUST
MHI PIONEER MUNICIPAL HIGH INCOME TRUST
NWPP NEW PEOPLES BANKSHARES INC.
FSK FS KKR CAPITAL CORP
RRBI RED RIVER BANCSHARES
HQL TEKLA LIFE SCIENCES INVESTORS
HQI HIREQUEST INC.
TLS TELOS
VPV INVESCO PA VALUE MUNI INC TST
MEGI MAINSTAY CBRE GBL INFRASTRUCTURE MEGATRENDS FD
MIO PIONEER MUN HIGH INCOME OPPORTUNITIES FD INC
Galectin Therapeutics Reports Financial Results for the Quarter Ended ...
Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2024 and Provides Business Update Fifth Data and Safety Monitoring Board (DSMB) meeting recommended the continuation, without modifications, of the Phase 2b/3 NAVIGATE study of belapectin in liver cirrhosis due to metabolic dysfunction-associated steatohepatitis (MASH)NAVIGATE trial remains on track for interim top-line readout late in the fourth quarter of 2024 NORCROSS, Ga., May 15, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported ...
- Jonathan Moreland
CNMD CONMED CORPORATION
HWBK HAWTHORN BANCSHARES
EFR ENERGY FUELS
ZOM ZOMEDICA PHARMACEUTICALS CORP
EYE NATIONAL VISION HOLDINGS
CDLX CARDLYTICS INC
ISDR ISSUER DIRECT CORP.
FSK FS KKR CAPITAL CORP
GO GROCERY OUTLET HOLDING
FNWB FIRST NORTHWEST BANCORP
FOUR SHIFT4 PAYMENTS
HQL INC.
TLS TEKLA LIFE SCIENCES INVESTORS
TMCI TELOS
FLYW TREACE MED CONCEPTS INC
BGS FLYWIRE CORP
DCGO B&G FOODS
BHVN INC.
GRNT DOCGO INC
VSTS_w BIOHAVEN LTD
BHRB GRANITE RIDGE RESOURCES INC
VESTIS CORPORATION
BURKE HERBERT FINANCIAL SERVICES CORP
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.